Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ExPEC9V vaccine to prevent invasive extraintestinal pathogenic E. coli disease in adults aged 60 years and older with prior urinary tract infection
NL-OMON58974Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in invasive extraintestinal pathogenic Escherichia coli disease (IED), urinary tract infection (UTI) and pyelonephritis comparing ExPEC9V with Placebo (2 arms). Primary endpoint: First IED event caused by ExPEC9V O-serotypes from blood or other sterile sites. Started May 2022; status: completed.
02
Drugs
ExPEC9V
03
Conditions
invasive extraintestinal pathogenic Escherichia coli disease (IED)urinary tract infection (UTI)pyelonephritis
Beyond the preview
Go deeper on NL-OMON58974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58974.